Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.
about
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patientsMetformin monotherapy for type 2 diabetes mellitusCalcimimetics for secondary hyperparathyroidism in chronic kidney disease patientsMetformin monotherapy for type 2 diabetes mellitusMarital quality and health: a meta-analytic reviewCurrent Controlled Trials: an opportunity to help improve the quality of clinical researchDebate: The slippery slope of surrogate outcomesThe usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptionsBack to thiazide-diuretics for hypertension: reflections after a decade of irrational prescribingThe benefits and threats of research partnerships with industryEffectiveness of general practice-based health checks: a systematic review and meta-analysisThe use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholdersDrug-Gene Interactions of Antihypertensive Medications and Risk of Incident Cardiovascular Disease: A Pharmacogenomics Study from the CHARGE ConsortiumNifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: protocol for an overview of systematic reviewsValidity and reliability of electroencephalographic frontal alpha asymmetry and frontal midline theta as biomarkers for depression.Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus.Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial LectureEnhancing prescription drug innovation and adoptionBiomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma.Salt and blood pressure. Conventional wisdom reconsidered.Surrogate end points in heart failure.Portfolio of clinical research in adult cardiovascular disease as reflected in ClinicalTrials.govInterpretation of observational studies.Traditional and novel risk factors in older adults: cardiovascular risk assessment late in life.Biomarkers and surrogate endpoints in glaucoma clinical trials.Do firms underinvest in long-term research? Evidence from cancer clinical trialsWhy do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?Institutional conflicts of interest: protecting human subjects, scientific integrity, and institutional accountability.Is suicide ideation a surrogate endpoint for geriatric suicide?Cost-effectiveness of blood glucose test strips in the management of adult patients with diabetes mellitus.Validation of self-reported periodontal disease: a systematic review.Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.Clinical trial design issues: at least 10 things you should look for in clinical trials.The risky reliance on small surrogate endpoint studies when planning a large prevention trial.Clinical trials and tribulations--lessons from pulmonary fibrosis.The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus.Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysisObservational research--opportunities and limitations.
P2860
Q24187385-58E3F303-4F14-480C-97AC-A08656C1EC19Q24187392-DC86E507-6902-485A-87EB-99A487EB8D4BQ24244091-97753AF2-B871-47C2-9B9C-60522854E1ABQ24246552-8704A656-6916-4328-B1E3-BD419A446694Q24626999-1FC1DDAE-1998-410B-A40C-86360F81E70EQ24792307-1569E791-7CFB-4A02-BFCD-5BFF525B4FA9Q24792578-639A8B4A-5EDF-4108-9C12-C1A7DCA944FAQ24793926-CE8E2010-5CE7-43B9-9E01-55FC055FC178Q24805075-6955CA7B-83F7-4CA8-9172-F242BE9B9471Q24810516-472F0CEF-6DD5-4D7A-8080-DC2087CCD3E0Q28307968-077A7AE2-E9CA-4EE8-BCD8-236DE79FE3B0Q28543430-E636116F-202D-4095-8EF3-7DADDD71432EQ28550578-A39CE55E-1438-4F75-8AFC-3986C5BB4ED0Q28578027-C218E1D9-4F9E-4D2F-8911-1E520C608E93Q29247935-CD777D63-F5C8-40E2-88D4-60591B413340Q30558549-2222BC89-CE3E-4A50-8CFA-8D4EFA3AEFF5Q32066328-0978AC80-6764-44F1-B885-77E34D649967Q33703000-00A5947F-54BB-4491-9894-9B5518FDCE3FQ33725286-7F235E1E-5DD5-4FC4-A610-A776E71026D2Q33756518-2D867D14-AD5F-493B-BD2A-9AFC34DFDC42Q34274534-A4668B10-A127-41DA-AF97-2C89799C63A0Q34564309-A496B0EC-171C-4BF2-887C-C9D66EF3A783Q35000520-3CC2A078-1399-484A-AC71-65F7DCF1AEFAQ35582653-EC31CA90-728D-43A4-813E-31EC57B577BFQ35686511-078DFBFD-0383-4C43-BEC5-852808302F7FQ35912696-70B9F458-B3F5-4501-A7C8-A1EF637F0F68Q36020575-2820DA39-1999-421A-94D1-BAF7D73435BDQ36022784-D7B98FF9-AE90-4283-A749-D5831479FE12Q36088088-DF7339BA-3547-41EE-9A7A-EB3217050C26Q36103356-1EC94669-366F-4FE2-A738-47B1CE1252BCQ36137741-DDB9AF22-452A-4251-B288-FACE0939363EQ36267738-0D70B61F-720B-4494-936D-B9A366EBF4E9Q36320595-0FFF8F5B-9A3E-4E91-BA27-DDB4C1EAF0A4Q36599365-E0A8C785-4C33-4752-AF7A-9D50FE9E0915Q36740585-2245AF25-CC76-4947-A30B-B5BB6CB9A48AQ36896973-5A6F4B34-92FA-4E98-9983-F7B76CEE3EF2Q37035523-3F5E3A6C-2DE3-495A-A23C-6EB4B0EECD87Q37057982-47AB6EF0-1F04-439E-B790-07FC23C99C2AQ37117293-CD921075-92C4-4506-B094-43E0A0F5F328Q37282191-867472AC-9FBA-4692-8FC2-091B1A1FB5E7
P2860
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Surrogate end points, health o ...... rs for cardiovascular disease.
@ast
Surrogate end points, health o ...... rs for cardiovascular disease.
@en
type
label
Surrogate end points, health o ...... rs for cardiovascular disease.
@ast
Surrogate end points, health o ...... rs for cardiovascular disease.
@en
prefLabel
Surrogate end points, health o ...... rs for cardiovascular disease.
@ast
Surrogate end points, health o ...... rs for cardiovascular disease.
@en
P2093
P356
P1476
Surrogate end points, health o ...... rs for cardiovascular disease.
@en
P2093
C D Furberg
D S Siscovick
E H Wagner
F R Rosendaal
R C Kaplan
S R Heckbert
P304
P356
10.1001/JAMA.282.8.786
P407
P577
1999-08-01T00:00:00Z